Oncology Institute, Inc. (TOIIW) — SEC Filings
Oncology Institute, Inc. (TOIIW) — 35 SEC filings. Latest: 8-K (Dec 1, 2025). Includes 21 8-K, 6 10-Q, 2 DEF 14A.
View Oncology Institute, Inc. on SEC EDGAR
Overview
Oncology Institute, Inc. (TOIIW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 14, 2025: On November 14, 2025, The Oncology Institute, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or disclosures detailed in the provided text. The company, formerly known as DFP Healthcare Acquisitions Corp., is incorporated in
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 3 bearish, 32 neutral. The dominant filing sentiment for Oncology Institute, Inc. is neutral.
Filing Type Overview
Oncology Institute, Inc. (TOIIW) has filed 21 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 2 10-K/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of TOIIW's 32 recent filings, 3 were flagged as high-risk, 13 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $136.564M |
| Net Income | -$16.504M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $27.658M |
| Operating Margin | N/A |
| Total Assets | $163.619M |
| Total Debt | $76.195M |
Key Executives
- Dr. David L. Smith
- Dr. Michael J. O'Connell
- Ms. Jennifer L. Smith
- Chief Executive Officer
- Dr. Robert L. Ferris
- Ms. Jennifer L. Jones
- Mr. David M. Miller
- Christopher Kersey
- Daniel Virnich
Industry Context
The oncology sector is characterized by high R&D costs, complex treatment protocols, and significant regulatory oversight. Companies in this space often operate with substantial financial needs due to the long development cycles and specialized nature of cancer care. Competitive pressures arise from established pharmaceutical giants, emerging biotech firms, and evolving treatment modalities like immunotherapy and personalized medicine.
Top Tags
financials (5) · healthcare (5) · financial-reporting (4) · 10-Q (4) · 8-K (3) · name-change (3) · governance (3) · Healthcare (3) · corporate-governance (3) · material-agreement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total operating revenue | $136.564M | Increased by 36.7% for the three months ended September 30, 2025, compared to $99.901M in 2024. |
| Net loss (Q3 2025) | $16.504M | Slightly higher than $16.113M in Q3 2024. |
| Net loss (YTD 2025) | $53.098M | Widened from $51.481M in YTD 2024. |
| Accumulated deficit | $263.911M | As of September 30, 2025, indicating significant historical losses. |
| Cash and cash equivalents | $27.658M | Decreased from $49.669M at December 31, 2024. |
| Net cash used in operating activities | $27.820M | For the nine months ended September 30, 2025. |
| Long-term debt prepayment | $20.000M | Made on February 26, 2025, reducing debt obligations. |
| Private placement gross proceeds | $16.500M | Received on March 24, 2025, boosting liquidity. |
| Clinic locations | 66 | Across five states, indicating operational scale. |
| SG&A expense reduction | 5% | Compared to the prior year same quarter, reflecting cost-cutting initiatives. |
| Net loss for Q2 2025 | $17.009M | Increased from $15.479M in Q2 2024 |
| Net loss for H1 2025 | $36.594M | Increased from $35.368M in H1 2024 |
| Total operating revenue for Q2 2025 | $119.802M | Increased from $98.578M in Q2 2024 |
| Dispensary revenue for Q2 2025 | $62.573M | Increased from $44.440M in Q2 2024 |
| Accumulated deficit as of June 30, 2025 | $247.407M | Increased from $210.813M at December 31, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Oncology Institute, Inc. (TOIIW)?
Oncology Institute, Inc. has 35 recent SEC filings from Jan 2024 to Dec 2025, including 21 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TOIIW filings?
Across 35 filings, the sentiment breakdown is: 3 bearish, 32 neutral. The dominant sentiment is neutral.
Where can I find Oncology Institute, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Oncology Institute, Inc. (TOIIW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Oncology Institute, Inc.?
Key financial highlights from Oncology Institute, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TOIIW?
The investment thesis for TOIIW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Oncology Institute, Inc.?
Key executives identified across Oncology Institute, Inc.'s filings include Dr. David L. Smith, Dr. Michael J. O'Connell, Ms. Jennifer L. Smith, Chief Executive Officer, Dr. Robert L. Ferris and 4 others.
What are the main risk factors for Oncology Institute, Inc. stock?
Of TOIIW's 32 assessed filings, 3 were flagged high-risk, 13 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Oncology Institute, Inc.?
Forward guidance and predictions for Oncology Institute, Inc. are extracted from SEC filings as they are enriched.